recombinant chimeric COVID-19 epitope DC vaccine

The recombinant chimeric COVID-19 epitope DC vaccine is an investigational subunit-based dendritic cell (DC) therapy designed for the prevention of SARS-CoV-2 infection (COVID-19). The approach involves isolating autologous peripheral blood mononuclear cells from a patient, differentiating monocytes into dendritic cells using GM-CSF and IL-4, and then pulsing these DCs with a recombinant SARS-CoV-2 spike (S) protein antigen. The S protein used is a pre-fusion stabilized ectodomain with the furin cleavage site removed and trimerization stabilized, based on the wild-type sequence. After incubation with lymphocytes, the resulting mixture—comprising 10% dendritic cells and 90% lymphocytes—is administered to subjects as an individualized cellular immunotherapy. This strategy aims to induce robust T-cell mediated immunity against SARS-CoV-2 by presenting viral epitopes directly via professional antigen-presenting cells[1][2][7]. Early clinical trials have demonstrated safety and immunogenicity in healthy volunteers.

Other names

dendritic cells vaccine